Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Gross Profit (2016 - 2025)

Lineage Cell Therapeutics' Gross Profit history spans 15 years, with the latest figure at $6.5 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 141.05% year-over-year to $6.5 million; the TTM value through Dec 2025 reached $14.4 million, up 57.23%, while the annual FY2025 figure was $14.4 million, 57.23% up from the prior year.
  • Gross Profit reached $6.5 million in Q4 2025 per LCTX's latest filing, up from $3.7 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $6.5 million in Q4 2025 to a low of $279000.0 in Q1 2021.
  • Average Gross Profit over 5 years is $2.4 million, with a median of $2.0 million recorded in 2023.
  • Peak YoY movement for Gross Profit: skyrocketed 1713.98% in 2022, then tumbled 61.02% in 2023.
  • A 5-year view of Gross Profit shows it stood at $964000.0 in 2021, then surged by 88.07% to $1.8 million in 2022, then rose by 1.05% to $1.8 million in 2023, then soared by 48.14% to $2.7 million in 2024, then soared by 141.05% to $6.5 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Gross Profit are $6.5 million (Q4 2025), $3.7 million (Q3 2025), and $2.7 million (Q2 2025).